Afuco™ Anti-Human IL2 ADCC Recombinant Antibody (MT204), ADCC Enhanced (CAT#: AFC-395CL)

Anti-IL2 ADCC Enhanced Antibody (MT204) is an ADCC enhanced antibody produced by our Afuco™ platform. MT204 is a humanized IgG1 antibody specific for interleukin-2 (IL-2) of human and rhesus monkey origin. MT204 has the potential to treat a wide variety of acute and chronic inflammatory diseases, including rheumatoid arthritis, asthma, acute transplant rejection, uveitis, psoriasis and multiple sclerosis. MT204 is the first humanized antibody targeting soluble human and non-human primate IL-2 by a unique mode of action, and has been shown in preclinical models to have inhibitory properties.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Bioactivity of MT204 with rhesus IL-2.

Figure 1 Bioactivity of MT204 with rhesus IL-2.

Rhesus monkey and human cells (mean of 4 monkeys and 4 humans) stimulated with ConA and blocked with MT204 at concentrations of 1, 10 and 100 μg/ml; (A) proliferation measured at day 4 is expressed as the percent response of unblocked cultures (medium, set at 100%); (B) IFN-gamma production of the same cultures was measured at day 2 or 3.

Plater-Zyberk, C., Estêvão, D. M. L., d'Argouges, S., Haanstra, K. G., Kondova, I., Vierboom, M., ... & Baeuerle, P. A. (2011). The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated. Transplant immunology, 25(2-3), 133-140.

Figure 2 MT204 serum concentration versus time.

Figure 2 MT204 serum concentration versus time.

A single 1-hour i.v. infusion of escalating doses of MT204 (2, 10 and 50 mg/kg) or 3 weekly repeat doses (50 mg/kg, 1 hour infusion) were administered to anesthetized rhesus monkeys (2 animals per group). Blood sampling was performed at different time points and serum samples were analyzed for MT204 concentrations. (A) Individual serum concentrations are plotted, normalized concentrations (C [ng/ml]/dose [μg/kg]) versus time profiles after administration of 2, 10 and 50 mg/kg MT204. (B) Cmax versus MT204 dose demonstrating dose-linearity of MT204, (C) serum concentration versus time after 3 weekly 1-hour infusions of 50 mg/kg MT204 to rhesus monkeys.

Plater-Zyberk, C., Estêvão, D. M. L., d'Argouges, S., Haanstra, K. G., Kondova, I., Vierboom, M., ... & Baeuerle, P. A. (2011). The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated. Transplant immunology, 25(2-3), 133-140.

Figure 3 Graft survival. Graft survival in the MT204-treated monkeys in comparison to the vehicle-treated control monkeys.

Figure 3 Graft survival. Graft survival in the MT204-treated monkeys in comparison to the vehicle-treated control monkeys.

(A) (B) mean data. MT204 was given at 50 mg/kg on days 0, 5 and 12 (unless rejection of the graft occurred earlier than day 12). Full rejection corresponds to complete necrosis of the graft. Statistical analysis comparing theMT204 and the control groups demonstrated significant difference between the two curves (p=0.025, Long-rank Mantel–Cox test). Historical controls are also depicted in graph (A), showing that the current controls reject in the same time frame. (B) Photographs of the grafts from monkeys pair P3 on days 9 and 12 posttransplantation. The upper two pictures show the grafts from the MT204-treated monkey, the lower two pictures show the grafts from the corresponding vehicletreated control. The MT204 allografts show no macroscopic signs of rejection on day 9 while the vehicle treated allografts show severe hemorrhages and necrosis in the morning of day 9; on day 12 the MT204 treated allografts show severe necrosis, but still part of the grafts is viable while the vehicle treated grafts show complete necrosis (this aspect was already seen on the afternoon of day 9).

Plater-Zyberk, C., Estêvão, D. M. L., d'Argouges, S., Haanstra, K. G., Kondova, I., Vierboom, M., ... & Baeuerle, P. A. (2011). The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated. Transplant immunology, 25(2-3), 133-140.

Figure 4 Peripheral blood cell phenotyping by FACS.

Figure 4 Peripheral blood cell phenotyping by FACS.

CD25+ expression in all animals treated with 50 mg/kg MT204 (two animals treated 1×, two animals treated 2× and 4 animals treated 3×). Cells were stained for CD3, CD4, and CD25 expression. An analysis window was set around lymphocytes that were CD3+CD4+ T cells, and the percentage of CD3+4+ T cells expressing high intensity CD25 (CD25++) was determined (see inset, which shows all CD3+4+ cells and the CD25bright window). The values taken before treatment were compared to the values after treatment. The stars indicate the level of significance (unpaired T-test). MT204 treated animals showed a significant decrease after treatment while buffer treated animals did not show such decrease. *pb0.05; **pb0.01; ***pb0.001.

Plater-Zyberk, C., Estêvão, D. M. L., d'Argouges, S., Haanstra, K. G., Kondova, I., Vierboom, M., ... & Baeuerle, P. A. (2011). The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated. Transplant immunology, 25(2-3), 133-140.

Figure 5 Drug exposure. MT204-treated animals were bled on different days over the course of the experiment and serum levels of MT204 determined by ELISA.

Figure 5 Drug exposure. MT204-treated animals were bled on different days over the course of the experiment and serum levels of MT204 determined by ELISA.

In all the control animals that received vehicle only, ELISA results were below the level of detection (0.2 μg/ml).

Plater-Zyberk, C., Estêvão, D. M. L., d'Argouges, S., Haanstra, K. G., Kondova, I., Vierboom, M., ... & Baeuerle, P. A. (2011). The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated. Transplant immunology, 25(2-3), 133-140.

Figure 6 Graft histology. H&E staining of graft biopsies taken after removal of graft cover on da moderate epithelial hyperplasia and hyperkeratosis.

Figure 6 Graft histology. H&E staining of graft biopsies taken after removal of graft cover on da moderate epithelial hyperplasia and hyperkeratosis.

Dermis: multifocal infiltrates of lymphocytes and neutrophils. (D, E, F skin: MT204 treated animal). Epidermis: few intraepidermal infiltrates, epithelial hyperplasia and orto- and para-keratotic hyperkeratosis. Dermis: multifocal infiltrates of lymphocytes, macrophages and few fibroblasts. (A,D Bar=200 μm; B,C,E,F Bar=100 μm). n = necrosis; h = hemorrhage; o = edema; eh = epithelial hyperplasia; l = lymphocytes; m = macrophages; neu = neutrophils; f = fibroblasts.

Plater-Zyberk, C., Estêvão, D. M. L., d'Argouges, S., Haanstra, K. G., Kondova, I., Vierboom, M., ... & Baeuerle, P. A. (2011). The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated. Transplant immunology, 25(2-3), 133-140.


Specifications

  • Host Species
  • Humanized
  • Derivation
  • Humanized
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Related Disease
  • Multiple Sclerosis; Rheumatoid Arthritis

Product Property

  • Purity
  • >95% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE
  • Storage
  • ≥1 year at -20°C. If the reconstituted antibody cannot be used within two weeks, it should be aliquoted into smaller vials and stored at -20°C

Target

  • Alternative Names
  • IL2; interleukin 2; IL-2; TCGF; lymphokine; interleukin-2; aldesleukin; T cell growth factor; involved in regulation of T-cell clonal expansion

Related Resources

  • Related Diseases

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Il2"

Single-domain Antibody

CAT Product Name Application Type
NABG-093 Recombinant Anti-Mouse Il2 VHH Single Domain Antibody ELISA, IHC, FC, FuncS Llama VHH

Deglycosylated Antibody (Non-glycosylated IgGs)

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0283MZ Chicken Anti-Interleukin-2 Polyclonal IgY WB, Indirect ELISA Chicken antibody

Blocking Antibody

CAT Product Name Application Type
NEUT-1309CQ Mouse Anti-IL2 Recombinant Antibody (VMC195) FC, Block Mouse IgG1
NEUT-1315CQ Rat Anti-Il2 Recombinant Antibody (clone 1A12), Biotin Block, ELISA, WB Rat IgG2a

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-1801 Rabbit Anti-IL2 Recombinant Antibody (clone DS1801AB) ICC, IHC-P, WB Rabbit IgG
MOR-4612 Rabbit Anti-IL2 Recombinant Antibody (clone TH125DS) WB, IHC-P Rabbit IgG

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for AFC-395CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare